NCT00320983已完成1 期
A Phase I Study of Adjuvant Topotecan and Cisplatin With Concurrent Radiation Therapy for Advanced Cervical Cancer
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 11
- 试验地点
- 2
- 主要终点
- disease progression
研究概览
简要总结
A Phase I Study of Adjuvant Topotecan and Cisplatin with Concurrent Radiation Therapy for Advanced Cervical Cancer.
详细描述
Examines the effects of Topotecan and Cisplatin with radiation for advanced cervical cancer
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Patients with histologically confirmed advanced cervical carcinoma who, following optional surgical staging, are not deemed to be curable by either surgery or radiotherapy alone. This includes patients with stages IIB, IIIA, IIIB or IVA and stages IB or IIA who in addition have one of the following risk factors:
- •Primary tumor > 6 cm
- •Positive pelvic and/or para-aortic lymph nodes (resected or unresected)
- •Positive surgical margins
- •Depth of invasion greater than 50 % and positive capillary-lymphatic space involvement
- •Eligible cell types include squamous, adenosquamous and adenocarcinoma of the cervix
- •Patients may have measurable disease (defined as lesions which can be measured in at least two (2) dimensions by physical examination or any medical imaging technique). Inability to measure disease will not constitute exclusion criteria.
- •Patients with GOG performance status of 0, 1, or
- •Patients will have recovered from the effects of recent surgery and should be free of clinically significant infection.
- •Patients must have adequate:
- •Bone marrow function: WBC greater than or equal to 3,000 cells/mm3, platelet count greater than or equal to 100,000 cells/mm3, and granulocyte count greater than or equal to 1,500 cells/mm
- •Renal function: Creatinine less than or equal to 2.0 mg/dl.
- •Hepatic function: Bilirubin less than or equal to 1.5 x institutional normal, SGOT and alkaline phosphatase less than or equal to 3 x institutional normal.
- •Patients must have signed an approved informed consent.
- •Patients have met the pre-entry requirements specified in Section 7.0
排除标准
- •Patients with GOG performance of 3 or
- •Patients with another malignancy, prior or concomitant, other than skin (excluding melanoma).
- •Patients with septicemia, severe infection, gastrointestinal bleeding, or intestinal obstruction.
- •Patients with anatomic abnormalities requiring modification of radiation fields (pelvic kidney, renal transplant, etc.).
- •Patient with recurrent cervical cancer
- •Patients who have received prior pelvic radiation
- •Pregnant women and women of childbearing potential not using an effective form of contraception.
- •History of thrombus (10/28/02)
- •History of unstable angina or MI within the past six months. Patients with evidence of abnormal cardiac conduction (e.g. bundle branch block, heart block) are eligible if their disease has been stable for the past six months. (10/28/02)
结局指标
主要结局
disease progression
时间窗: disease progress or complete remission
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
Topotecan and Radiation Therapy in Treating Patients With Solid Tumors or LymphomaLung CancerLymphomaEsophageal CancerNCT00002625National Cancer Institute (NCI)5
已完成
1 期
Topotecan, Cisplatin, and Radiation Therapy in Treating Patients With Advanced Cervical CancerCervical CancerNCT00287911Masonic Cancer Center, University of Minnesota18
已完成
1 期
Radiation Therapy Plus Topotecan in Treating Patients With Non-small Cell Lung CancerLung CancerNCT00002537National Cancer Institute (NCI)20
已完成
2 期
Sutent Following Chemotherapy, Radiation and Surgery For Resectable Esophageal CancerEsophageal CancerNCT00400114University Health Network, Toronto36
已完成
3 期
Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical CancerCervical AdenocarcinomaCervical Adenosquamous CarcinomaCervical Squamous Cell Carcinoma, Not Otherwise SpecifiedStage IB Cervical Cancer AJCC v6 and v7Stage IIA Cervical Cancer AJCC v7Stage IIB Cervical Cancer AJCC v6 and v7Stage IIIB Cervical Cancer AJCC v6 and v7Stage IVA Cervical Cancer AJCC v6 and v7NCT01414608GOG Foundation926